Aligos Therapeutics Shares Soar on Major China Licensing Agreement and Regulatory Milestone for Chronic Hepatitis B Treatment

Aligos Therapeutics announces $25 million upfront payment and Breakthrough Therapy Designation in China for pevifoscorvir sodium.